Antibody Ingredients TRIZ Cases

A bispecific antigen-binding molecule targets BCMA and CD3 to activate T cells.

A targeted micelle nanoconjugate delivers therapeutic agents to tumor sites via scFv binding.

Membrane vesicle immunization generates antibodies that detect the native endothelin receptor sub-type B on cancer cells without solubilization artifacts.

Long peptides of at least 12 amino acids overcome MHC variability and low affinity binding to accelerate CD4+ T-cell responses alongside checkpoint inhibitors.

Specialized CDR regions enable binding to retained MUC16-C after N-terminal shedding, addressing ineffective coverage of truncated antigens.

Norleucine substitution in antibody CDRs overcomes limited affinity and duration of action for SSEA4-targeted cancer therapy.

Antibody-drug conjugates target B7-H4 to kill cancer cells while sparing healthy tissue.

Anti-TIM3 antibody administration resolves TIM3 inhibition reliability by enabling flexible dosing regimens that enhance immune responses against cancer.

Anti-alpha-synuclein antibodies alter protein efflux from the brain to blood, enabling non-invasive diagnosis of elevated alpha-synuclein levels.

Bispecific antibodies bind ALK-1 and BMPR-2 receptors to restore endothelial signaling, avoiding osteogenic side effects of direct BMP-9 therapy.

Anti-TIGIT antibodies mediate antibody-dependent cell-mediated cytotoxicity despite insufficient efficacy in existing therapies.

Adding zinc ions or adjusting osmolality reduces antibody charge variant heterogeneity.

Monoclonal antibodies bind human PD-L1 to block immune checkpoints, overcoming patient resistance in cancer therapy.

A CD38 antibody binds human CD38 to activate immune cells and kill tumor targets.

Bacterial expression of recombinant ETAR proteins enables high-affinity antibody generation, resolving purification complexity.

Incorporating non-canonical amino acids at predetermined positions enables homogeneous drug-to-antibody ratios and improves therapeutic efficacy.

Bispecific antibodies bridge TSLPR-positive leukemia cells with CD3 epsilon on T cells, activating targeted cytotoxicity against Ph-like B-ALL.

Segmented epitope recognition enables specific antibody development to resolve the bottleneck of limited therapeutic agents for lung cancer metastasis.

Anti-ASCT2 antibody-drug conjugates deliver cytotoxins to ASCT2-overexpressing cancer cells, reducing drug-related toxicities.

Engineered antibodies resolve non-specific binding trade-offs by selectively blocking ASIC1-mediated signaling to treat pain disorders.

Fc region mutations stabilize CD27 antibody dimers during storage while preserving high affinity binding and NF-kB activation.

Anti-IL1-RAP antibodies target cancer stem cells to overcome chemotherapy toxicity and recurrence risks.

A humanized anti-CD47 antibody uses CDR-grafting to replace mouse framework regions with human sequences.

Site-specific cysteine mutations eliminate antibody-drug conjugate heterogeneity and improve manufacturing precision.

High-affinity monoclonal antibodies target PfCSP to neutralize sporozoites, addressing modest vaccine efficacy and drug resistance.

Single-domain antibody fragments target human FOLR1 to deliver therapeutic agents across the blood-brain barrier while minimizing side effects.

Dual therapy merges STAT3 inhibition with checkpoint blockade to overcome immune resistance mechanisms limiting monotherapy efficacy.

A protease-cleavable peptide linker connects a drug molecule to an inhibitory binder, releasing active therapy at the tumor site to reduce systemic toxicity.

Engineered Fc domain mutations increase affinity for FcRn at acidic pH, extending serum half-life while maintaining low binding at neutral pH.

Engineered anti-SIRPalpha antibodies minimize red blood cell binding to prevent anemia while maintaining therapeutic efficacy.

Anti-TIM-3 antibodies block signaling pathways to reverse T cell exhaustion and enhance cytokine secretion.

Antibody targeting EGFR inhibits gastric cancer cell migration, preventing metastasis when conventional treatments fail.

Knobs-into-holes Fc mutations resolve heavy chain mismatch during expression, enabling stable bispecific assembly.

Human anti-CD99 antibody resolves toxicity and stability trade-offs by inducing selective apoptosis in T-ALL cells.

Novel anti-CD20 antibodies with engineered Fc regions enhance binding potency and serum half-life.

A multivalent antibody employs a competing second molecule to enhance binding specificity, reducing toxicity from normal cell engagement.

Antibody targeting CAPRIN-1 polypeptide delivers antitumor activity while sparing normal cells from adverse reactions.

Antibodies targeting CD4 domain 1 eliminate latent HIV reservoirs, preventing viral rebound after HAART cessation.

Combines anti-PD-1, TIM-3, and LAG-3 antibodies to overcome single-agent efficacy limits.

A bispecific antigen-binding construct links CD3 on immune cells to Robo1 on tumor cells.

Anti-AGE antibodies eliminate senescent cells to address sarcopenia, overcoming the lack of FDA-approved agents.

High-affinity antibodies target tumor-associated carbohydrate antigens to reduce tumor volume and improve patient outcomes.

Humanized B7-H3 antibody drug conjugates deliver cytotoxic payloads to tumors, reducing immunogenicity while enhancing cancer treatment efficacy.

Specific antibodies inhibit TGF-β activation by binding integrin αvβ8, resolving the trade-off between therapeutic effectiveness and development complexity.

The 14A5.2 antibody targets a unique Nectin-4 epitope, enabling treatment of cancers resistant to existing therapies.

Combines anti-CD20 binding molecules with immunostimulatory agents to promote B-cell killing, increasing myeloid cell infiltration at the tumor site.

Segment patient populations into distinct immunotypes via peripheral blood marker profiling to predict immune checkpoint blockade response without tumor tissue.